Vaginal Delivery of Repros' Proellex Bypasses First Pass Liver Effects

Repros Therapeutics Inc.

today announced it has completed two animal model studies of the use of Proellex in a vaginally administered formulation that demonstrated effects on progesterone sensitive tissues equivalent to the highest oral dose formerly in development by the Company.